Remegen Co Ltd

Price Chart

Risk-Adjusted Performance

Remegen Co Ltd (9995) Price Performance

Remegen Co Ltd (9995) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD93.20, down 4.90% from the previous close.

Over the past year, 9995 has traded between a low of HKD20.15 and a high of HKD125.00. The stock has gained 358.0% over this period. It is currently 25.4% below its 52-week high.

Remegen Co Ltd has a market capitalization of $57.00B, with a price-to-earnings ratio of 82.59.

About Remegen Co Ltd

RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for the treatment of various cancers. It also develops products in various stages, including RC-28E, a fusion protein that targets vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF); RC88, an antibody-drug conjugate (ADC) that targets mesothelin; and RC148, a bispecific antibody ADC drug that in Phase1/2 clinical studies targeting program cell death protein 1 (PD-1) and VEGF; RC278, an ADC drug for the treatment of multiple solid tumors; and RC288, a dual-antibody ADC drug for the treatment of various tumors. The company was founded in 2008 and is headquartered in Yantai, the People's Republic of China.